nadp has been researched along with Retinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belyaeva, OV; Kedishvili, NY; Lee, SA; Popov, IK | 1 |
| Chen, CF; Ko, ML; Peng, PH | 1 |
2 other study(ies) available for nadp and Retinal Diseases
| Article | Year |
|---|---|
Overproduction of bioactive retinoic acid in cells expressing disease-associated mutants of retinol dehydrogenase 12.
Topics: Alcohol Oxidoreductases; Amino Acid Substitution; Animals; Apoptosis; Gene Expression Regulation, Enzymologic; Genetic Diseases, Inborn; Homeostasis; Humans; Light; Macaca mulatta; Mice; Mice, Mutant Strains; Mutation, Missense; NADP; Oxidation-Reduction; Photoreceptor Cells; Retinal Diseases; Retinaldehyde; Rhodopsin; Tretinoin | 2007 |
Epigallocatechin-3-gallate reduces retinal ischemia/reperfusion injury by attenuating neuronal nitric oxide synthase expression and activity.
Topics: Animals; Antioxidants; Apoptosis; Catechin; Cell Death; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Glial Fibrillary Acidic Protein; In Situ Nick-End Labeling; Lipid Peroxidation; NADP; Neuroprotective Agents; Nitric Oxide Synthase; Rats; Rats, Wistar; Reperfusion Injury; Retinal Diseases; Retinal Ganglion Cells | 2008 |